Early Ramucirumab/Paclitaxel vs Continuation of First-line Chemotherapy in Advanced HER2-negative Gastric/Gastroesophageal Cancer
1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR ...
Tag: Ramucirumab
Ramucirumab fails in HER2-negative advanced breast cancer
1. The addition of ramucirumab, a VEGF-2 receptor blocker, to docetaxel did not significantly increase progression free or overall survival in ...